Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CTXCVE:MPHNYSEARCA:QPTNASDAQ:REUN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.55-1.8%C$0.56C$0.41▼C$0.69C$10.12M1.6914,494 shs9,682 shsMPHMedicureC$0.87+4.8%C$0.82C$0.63▼C$1.26C$9.08M0.94,930 shs500 shsQPTAdvisorShares Q Portfolio Blended Allocation ETF$19.10+0.1%$19.10$18.63▼$27.54$1.91MN/A1,912 shs19,400 shsREUNReunion Neuroscience$1.12$1.12$0.63▼$5.07$13.13M2.29210,209 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%-3.45%+5.66%+1.82%+28.74%MPHMedicure0.00%0.00%+6.41%+15.28%-27.83%QPTAdvisorShares Q Portfolio Blended Allocation ETF0.00%0.00%0.00%0.00%0.00%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXCrescita TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXCrescita Therapeutics 0.00N/AN/AN/AMPHMedicure 0.00N/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF 0.00N/AN/AN/AREUNReunion Neuroscience 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXCrescita TherapeuticsC$16.62M0.61C$0.46 per share1.20C$0.83 per share0.66MPHMedicureC$21.08M0.43C$0.35 per share2.49C$1.91 per share0.45QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/AREUNReunion Neuroscience$3.88M3.38N/AN/A$1.37 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXCrescita Therapeutics-C$2.61M-C$0.15N/A∞N/A-15.73%-15.60%-8.26%N/AMPHMedicure-C$2.03M-C$0.19N/A∞N/A-9.65%-10.18%-5.63%N/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/A0.00∞N/AN/AN/AN/AN/AREUNReunion Neuroscience-$36.69MN/A0.00N/AN/AN/A-91.82%-64.58%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXCrescita TherapeuticsN/AN/AN/AN/AN/AMPHMedicureN/A2.24%N/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF$0.080.42%N/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXCrescita Therapeutics5.772.702.29MPHMedicure4.652.031.29QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AREUNReunion NeuroscienceN/A3.513.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXCrescita TherapeuticsN/AMPHMedicure23.10%QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AREUNReunion Neuroscience12.88%Insider OwnershipCompanyInsider OwnershipCTXCrescita Therapeutics10.87%MPHMedicure26.68%QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AREUNReunion NeuroscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXCrescita Therapeutics6218.41 millionN/ANot OptionableMPHMedicureN/A10.44 millionN/ANot OptionableQPTAdvisorShares Q Portfolio Blended Allocation ETFN/A100,000N/ANot OptionableREUNReunion Neuroscience1611.72 millionN/ANot OptionableREUN, MPH, QPT, and CTX HeadlinesRecent News About These CompaniesLSD for Anxiety and Depression: Worth the Trip?May 8, 2025 | medscape.comPostpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesApril 7, 2025 | theglobeandmail.comReunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the ...April 7, 2025 | bakersfield.comReunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 ConferenceApril 7, 2025 | globenewswire.comReunion Neuroscience Announces Participation in Premiere Maternal Mental Health EventMarch 4, 2025 | globenewswire.com5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJanuary 23, 2025 | finance.yahoo.comAre Indian brands prepared for neuroscience-backed advertising in 2025?January 7, 2025 | bestmediainfo.comReunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 MilestonesJanuary 6, 2025 | globenewswire.comReunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual MeetingDecember 11, 2024 | globenewswire.comTwenty-First-Century GriefNovember 11, 2024 | psychologytoday.comBeethoven’s Ninth and the Ode to Joy: Symphony and PsycheOctober 14, 2024 | psychologytoday.comReunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health DisordersOctober 9, 2024 | globenewswire.comCottage Children’s Medical Center Hosts NICU Reunion at Santa Barbara ZooOctober 3, 2024 | independent.comTo Motivate Teens, Ask “Who’s Your Future Self?”September 18, 2024 | edutopia.orgReunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical OfficerSeptember 10, 2024 | globenewswire.comBringing together world-class neuroscience to advance research and clinical careSeptember 9, 2024 | bristol.ac.ukReunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention MonthSeptember 4, 2024 | globenewswire.comApes Have Never Asked Questions Despite Scientists Communicating with Them Since '60s?September 2, 2024 | snopes.comEssential Neuroscience for PsychiatristsSeptember 2, 2024 | cambridge.orgCompassionate and commonsense therapeutic approachSeptember 1, 2024 | theage.com.auNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREUN, MPH, QPT, and CTX Company DescriptionsCrescita Therapeutics TSE:CTXC$0.55 -0.01 (-1.79%) As of 03:00 PM EasternCrescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.Medicure CVE:MPHC$0.87 +0.04 (+4.82%) As of 01:24 PM EasternMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.AdvisorShares Q Portfolio Blended Allocation ETF NYSEARCA:QPT$19.10 +0.01 (+0.05%) As of 10/28/2022Reunion Neuroscience NASDAQ:REUNReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
